ALDX

1.485

3.57% -0.055

Vorhandelsmarkt: 1.59 0.105 +7.07%

Aldeyra Therapeutics Inc (ALDX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$1.54

Offen:

$1.52

24-Stunden-Volumen:

547.97K

Relative Volume:

0.41

Marktkapitalisierung:

$89.58M

Einnahmen:

Nettoeinkommen (Verlust:

$-27.37M

KGV:

-3.2623

EPS:

-0.4552

Netto-Cashflow:

$-25.99M

1W Leistung:

-2.30%

1M Leistung:

-6.01%

6M Leistung:

-72.80%

1J Leistung:

-74.66%

1-Tages-Spanne:

$1.48

$1.56

1-Wochen-Bereich:

$1.4601

$1.581

52-Wochen-Spanne:

$1.07

$5.93

Aldeyra Therapeutics Inc Stock (ALDX) Company Profile

Firmenname

Aldeyra Therapeutics Inc

Sektor

Healthcare (1080)

Branche

Biotechnology (605)

Telefon

781-761-4904

Adresse

131 HARTWELL AVENUE, LEXINGTON, MA

Mitarbeiter

Twitter

@aldeyraaldx

Nächster Verdiensttermin

2026-08-06

Neueste SEC-Einreichungen

ALDX's Discussions on Twitter

Compare ALDX vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ALDX Aldeyra Therapeutics Inc	1.485	90.49M	0	-27.37M	-25.99M	-0.4552
VRTX Vertex Pharmaceuticals Inc	541.69	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	794.19	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,023.21	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	137.99	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	207.88	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-18	Herabstufung	H.C. Wainwright	Buy → Neutral
2024-04-03	Hochstufung	Oppenheimer	Perform → Outperform
2024-04-02	Fortgesetzt	H.C. Wainwright	Buy
2022-04-27	Fortgesetzt	H.C. Wainwright	Buy
2021-02-08	Eingeleitet	H.C. Wainwright	Buy
2020-12-16	Eingeleitet	Berenberg	Buy
2020-10-30	Eingeleitet	Jefferies	Buy
2020-10-16	Eingeleitet	BTIG Research	Buy
2020-09-22	Eingeleitet	Alliance Global Partners	Buy
2020-05-12	Eingeleitet	Oppenheimer	Outperform
2018-12-04	Eingeleitet	Citigroup	Buy
2018-09-26	Bestätigt	Cantor Fitzgerald	Overweight
2018-09-13	Eingeleitet	Janney	Buy
2018-01-26	Eingeleitet	Seaport Global Securities	Buy
2016-09-26	Eingeleitet	H.C. Wainwright	Buy
2016-07-01	Eingeleitet	Stifel	Buy
2015-07-01	Eingeleitet	Canaccord Genuity	Buy
2015-03-25	Eingeleitet	Chardan Capital Markets	Buy
2015-03-20	Bestätigt	H.C. Wainwright	Buy
2014-11-18	Eingeleitet	H.C. Wainwright	Buy
2014-06-19	Eingeleitet	Aegis Capital	Buy

Alle ansehen

Aldeyra Therapeutics Inc Aktie (ALDX) Neueste Nachrichten

Aug 19, 2026

Research Analysts Issue Forecasts for ALDX Q3 Earnings - MarketBeat

Aug 19, 2026

Aug 18, 2026

AQR Capital Management Expands Aldeyra Therapeutics (ALDX) Stake Despite Steep Stock Decline - GuruFocus

Aug 18, 2026

HC Wainwright Has Optimistic Outlook of ALDX FY2030 Earnings - MarketBeat

Aug 18, 2026

Aug 17, 2026

H.C. Wainwright Maintains Aldeyra Therapeutics(ALDX.US) With Hold Rating, Maintains Target Price $2 - Moomoo

Aug 17, 2026

Aug 16, 2026

Aldeyra Therapeutics (ALDX) Climbs 8.33% as Biotech Stock Approaches Resistance at $1.64Covered Call Trade - Vinanet

Aug 16, 2026

Aug 15, 2026

Aldeyra Therapeutics (NASDAQ:ALDX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat

Aug 15, 2026

Aug 12, 2026

Aldeyra Therapeutics (ALDX): AQR Capital discloses 6.22% beneficial ownership stake - Stock Titan

Aug 12, 2026

ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review

Aug 12, 2026

Aug 11, 2026

ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review

Aug 11, 2026

Aug 09, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect - ACCESS Newswire

Aug 09, 2026

Aug 07, 2026